AU2002212441A1 - Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain - Google Patents

Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain

Info

Publication number
AU2002212441A1
AU2002212441A1 AU2002212441A AU1244102A AU2002212441A1 AU 2002212441 A1 AU2002212441 A1 AU 2002212441A1 AU 2002212441 A AU2002212441 A AU 2002212441A AU 1244102 A AU1244102 A AU 1244102A AU 2002212441 A1 AU2002212441 A1 AU 2002212441A1
Authority
AU
Australia
Prior art keywords
vanilloid
agonists
antagonists
pain
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212441A
Inventor
John Beresford Davis
Julie Egerton
Martin James Gunthorpe
Darren Smart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2002212441A1 publication Critical patent/AU2002212441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002212441A 2000-10-25 2001-10-25 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain Abandoned AU2002212441A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0026114 2000-10-25
GB0026114.9 2000-10-25
GBGB0026114.9A GB0026114D0 (en) 2000-10-25 2000-10-25 New use
PCT/GB2001/004739 WO2002034280A2 (en) 2000-10-25 2001-10-25 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain

Publications (1)

Publication Number Publication Date
AU2002212441A1 true AU2002212441A1 (en) 2002-05-06

Family

ID=9901947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212441A Abandoned AU2002212441A1 (en) 2000-10-25 2001-10-25 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain

Country Status (6)

Country Link
US (2) US20040198649A1 (en)
EP (1) EP1328807A2 (en)
JP (1) JP2004512310A (en)
AU (1) AU2002212441A1 (en)
GB (1) GB0026114D0 (en)
WO (1) WO2002034280A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060621A1 (en) * 2004-09-07 2006-06-29 Smithkline Beecham Corp 1,3-ACYCLIC DIAMINES AS AGONISTS OF TRPV4 CHANNEL RECEPTORS
EP1796677A4 (en) * 2004-09-07 2009-07-08 Smithkline Beecham Corp Method for activating trpv4 channel receptors by agonists
EP2869897A4 (en) 2012-07-06 2016-09-28 Univ Duke Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
CN109310683A (en) 2016-04-07 2019-02-05 杜克大学 The small molecular double inhibitor of TRPV4 and TRPA1 for sterilizing and anaesthetizing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037811A (en) * 1990-04-17 1991-08-06 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5185430A (en) * 1987-10-16 1993-02-09 University Of Georgia Research Foundation, Inc. Antigen recognized by natural killer and non-specific cytotoxic cells
US5461070A (en) * 1994-08-29 1995-10-24 The Regents Of The University Of California Anti-flammatory method using indole alkaloids
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
CA2359955A1 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Human vanilloid receptor gene
US6455278B1 (en) * 2000-02-08 2002-09-24 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding human vanilloid receptor VR3
AU2001247460A1 (en) * 2000-03-15 2001-09-24 Millennium Pharmaceuticals, Inc. 18615 and 48003, human ion channels and uses therefor
EP1170365A1 (en) * 2000-07-04 2002-01-09 Smithkline Beecham Plc Member of the ion channel family of polypeptides; vanilrep4

Also Published As

Publication number Publication date
JP2004512310A (en) 2004-04-22
WO2002034280A2 (en) 2002-05-02
US20070161560A1 (en) 2007-07-12
GB0026114D0 (en) 2000-12-13
WO2002034280A3 (en) 2002-07-18
US20040198649A1 (en) 2004-10-07
EP1328807A2 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
HK1066534A1 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
HUP0104696A3 (en) Pharmaceutical composition containing 5ht1 receptor agonists and metoclopramide for the treatment of migraine
HUP0200553A3 (en) Use of pyridine derivatives as mglur5 antagonists producing pharmaceutical compositions suitable for the treatment of pain and anxiety
AU4134101A (en) Hormone receptor functional entities and methods of their use
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
IL198759A (en) Use of gal3 receptor antagonists for the preparation of medicaments for treatment of depression and/or anxiety
AU6482200A (en) Use of amh and/or amh agonists and/or amh antagonists for long-term control of female fertility
HK1059080A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl- acetic acid and the use thereof for treating migraines and pain
AU2002212441A1 (en) Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
EP1324763A4 (en) Stat3 agonists and antagonists and therapeutic uses thereof
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU3031097A (en) Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
ID28817A (en) USE OF TETRAHIDROPIRIDIN (OR 4-HIDROPIPERIDIN) -BUTILAZOL DRUGS IN THE MAKING OF DRUGS FOR PAIN TREATMENT
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002321767A1 (en) Tr xidatin agonists and antagonists treatment of metabolic disorders
AU2002334250A1 (en) Xafinix agonists and antagonists for use in the treatment of metabolic disorders
AU2002339674A1 (en) Ditacin agonists and antagonists for use in the treatment of metabolic disorders
AU2002324296A1 (en) Agonists and antagonists of energen for use in the treatment of metabolic disorders
AU2002321774A1 (en) Agonists and antagonists of contabix for use in the treatment of metabolic disorders
AU2002324288A1 (en) Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
AU2002313578A1 (en) Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders